Perioperative Imniune Checkpoint Inhibition in Early-Stage Non-Small. Cell Lung Cancer A Review

被引：35

作者：

Desai, Aakash P. ^{[1
]}

Adashek, Jacob J. ^{[2
]}

Reuss, Joshua E. ^{[3
]}

West, Howard Jack ^{[4
]}

Mansfield, Aaron S. ^{[1
]}

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN 55902 USA

[2] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21287 USA

[3] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

来源：

JAMA ONCOLOGY | 2023年 / 9卷 / 01期

关键词：

LIGAND; 1; EXPRESSION; NEOADJUVANT CHEMOTHERAPY; OPEN-LABEL; PLUS CHEMOTHERAPY; SINGLE-ARM; PHASE-III; MRD PLUS; NSCLC; ADJUVANT; DURVALUMAB;

D O I：

10.1001/jamaoncol.2022.5389

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IMPORTANCE Although cancer-related mortality continues to decline, lung cancer remains the No. 1 cause of cancer deaths in the US. Almost half of the patients with non-small cell lung cancer (NSCLC) are diagnosed with early-stage, local or regional disease and are at high risk of recurrence within 5 years of diagnosis. OBSERVATIONS Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with metastatic NSCLC and have recently been tested in multiple clinical trials to determine their efficacy in the neoadjuvant or adjuvant setting for patients with local or regional disease. The landscape for perioperative ICIs in lung cancer is evolving rapidly, with recently reported and soon to mature clinical trials; however, the recent data highlight the potential of ICIs to increase response rates and decrease rates of relapse in early stages of lung cancer. Concurrently, novel applications of cell-free DNA may guide perioperative management strategies. CONCLUSIONS AND RELEVANCE This article reviews the various approaches of incorporating perioperative use of immunotherapeutic agents for the treatment of early stages of NSCLC.

引用

页码：135 / 142

页数：8

共 52 条

[41] Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer [J].

Reuss, Joshua E. ;

Anagnostou, Valsamo ;

Cottrell, Tricia R. ;

Smith, Kellie N. ;

Verde, Franco ;

Zahurak, Marianna ;

Lanis, Mara ;

Murray, Joseph C. ;

Chan, Hok Yee ;

McCarthy, Caroline ;

Wang, Daphne ;

White, James R. ;

Yang, Stephen ;

Battafarano, Richard ;

Broderick, Stephen ;

Bush, Errol ;

Brock, Malcolm ;

Ha, Jinny ;

Jones, David ;

Merghoub, Taha ;

Taube, Janis ;

Velculescu, Victor E. ;

Rosner, Gary ;

Illei, Peter ;

Pardoll, Drew M. ;

Topalian, Suzanne ;

Naidoo, Jarushka ;

Levy, Ben ;

Hellmann, Matthew ;

Brahmer, Julie R. ;

Chaft, Jamie E. ;

Forde, Patrick M. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[42] Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status [J].

Ricciuti, Biagio ;

Arbour, Kathryn C. ;

Lin, Jessica J. ;

Vajdi, Amir ;

Vokes, Natalie ;

Hong, Lingzhi ;

Zhang, Jianjun ;

Tolstorukov, Michael Y. ;

Li, Yvonne Y. ;

Spurr, Liam F. ;

Cherniack, Andrew D. ;

Recondo, Gonzalo ;

Lamberti, Giuseppe ;

Wang, Xinan ;

Venkatraman, Deepti ;

Alessi, Joao, V ;

Vaz, Victor R. ;

Rizvi, Hira ;

Egger, Jacklynn ;

Plodkowski, Andrew J. ;

Khosrowjerdi, Sara ;

Digumarthy, Subba ;

Park, Hyesun ;

Vaz, Nuno ;

Nishino, Mizuki ;

Sholl, Lynette M. ;

Barbie, David ;

Altan, Mehmet ;

Heymach, John, V ;

Skoulidis, Ferdinandos ;

Gainor, Justin F. ;

Hellmann, Matthew D. ;

Awad, Mark M. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) :399-410

[43] SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial [J].

Rothschild, Sacha, I ;

Zippelius, Alfred ;

Eboulet, Eric, I ;

Prince, Spasenija Savic ;

Betticher, Daniel ;

Bettini, Adrienne ;

Frueh, Martin ;

Joerger, Markus ;

Lardinois, Didier ;

Gelpke, Hans ;

Mauti, Laetitia A. ;

Britschgi, Christian ;

Weder, Walter ;

Peters, Solange ;

Mark, Michael ;

Cathomas, Richard ;

Ochsenbein, Adrian F. ;

Janthur, Wolf-Dieter ;

Waibel, Christine ;

Mach, Nicolas ;

Froesch, Patrizia ;

Buess, Martin ;

Bohanes, Pierre ;

Godar, Gilles ;

Rusterholz, Corinne ;

Gonzalez, Michel ;

Pless, Miklos .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) :2872-+

[44] Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial [J].

Shu, Catherine A. ;

Gainor, Justin F. ;

Awad, Mark M. ;

Chiuzan, Codruta ;

Grigg, Claud M. ;

Pabani, Aliyah ;

Garofano, Robert F. ;

Stoopler, Mark B. ;

Cheng, Simon K. ;

White, Abby ;

Lanuti, Michael ;

D'Ovidio, Frank ;

Bacchetta, Matthew ;

Sonett, Joshua R. ;

Saqi, Anjali ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2020, 21 (06) :786-795

[45] Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities [J].

Skoulidis, Ferdinandos ;

Byers, Lauren A. ;

Diao, Lixia ;

Papadimitrakopoulou, Vassiliki A. ;

Tong, Pan ;

Izzo, Julie ;

Behrens, Carmen ;

Kadara, Humam ;

Parra, Edwin R. ;

Canales, Jaime Rodriguez ;

Zhang, Jianjun ;

Giri, Uma ;

Gudikote, Jayanthi ;

Cortez, Maria A. ;

Yang, Chao ;

Fan, Youhong ;

Peyton, Michael ;

Girard, Luc ;

Coombes, Kevin R. ;

Toniatti, Carlo ;

Heffernan, Timothy P. ;

Choi, Murim ;

Frampton, Garrett M. ;

Miller, Vincent ;

Weinstein, John N. ;

Herbst, Roy S. ;

Wong, Kwok-Kin ;

Zhang, Jianhua ;

Sharma, Padmanee ;

Mills, Gordon B. ;

Hong, Waun K. ;

Minna, John D. ;

Allison, James P. ;

Futreal, Andrew ;

Wang, Jing ;

Wistuba, Ignacio I. ;

Heymach, John V. .

CANCER DISCOVERY, 2015, 5 (08) :860-877

[46] MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD plus after curative-intent therapy [J].

Spigel, D. R. ;

Peters, S. ;

Ahn, M-J. ;

Tsuboi, M. ;

Chaft, J. ;

Harpole, D. ;

Barlesi, F. ;

Abbosh, C. ;

Mann, H. ;

May, R. ;

Dennis, P. A. ;

Swanton, C. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) :S745-S746

[47]

Surveillance Epidemiology and End Results (SEER) Program, LUNG BRONCH STAG DIS

[48]

The Centers for Disease Control and Prevention, This study identifies the negative effect of obesity on amount of oocytes retrieved, and the higher amount of FSH needed in this cohorts

[49]

U.S. Food and Drug Administration, 2020, FDA approves first adjuvant therapy for most common type of lung cancer

[50]

U.S. Food and Drug Administration, 2022, FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer

← 1 2 3 4 5 6 →